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Introduction: A 51 year-old woman was diagnosed with endometrial cancer (EC) and 
underwent surgical staging. Pathological evaluation showed a 2 cm × 1 cm G2 endo-
metrioid EC with a 30% myometrial deep invasion (FIGO Stage 1A). The patient was 
classified as low risk of recurrence, and no adjuvant treatment was offered. Six months 
after surgery, the patient developed an early vescico-vaginal recurrence, and chemother-
apy treatment was started. Few months later, a subsequent involvement of vaginal wall, 
ileum, and omentum was detected, and the patient underwent second surgery.
Background: LH/hCG-receptor (LH/hCG-R) expression has been previously reported 
to be associated with an invasive phenotype in EC cells. Moreover, in a preclinical mouse 
model of EC behaves as a prometastatic molecular device.
Discussion: We analyzed the expression level of LH/hCG-R in cancer specimens 
 collected during surgeries. Molecular and immunohistochemical analyses showed a 
strong expression of both mRNA and protein for LH/hCG-R in all specimens.
Conclusion: LH/hCG-R expression may be assessed together with other clinicopatho-
logical parameters in order to better predict the risk of recurrence in low-risk EC patients. 
Further clinical trials are warranted in order to validate LH/hCG-R as biomarker in EC.
Keywords: endometrial cancer, biomarker, LH/hCG-receptor, recurrence, immunohistochemical analysis, 
molecular analysis
INtRoDUCtIoN
A 51-year-old postmenopausal woman presented with abnormal vaginal bleeding in December 
2014. Ultrasound examination revealed a polypoid lesion in the uterine fundus. Office hysteroscopy 
with biopsy was performed and revealed a G2 endometrioid adenocarcinoma of the endometrium. 
A  pelvic magnetic resonance imaging (MRI) demonstrated in T2-weighted image a 2 cm × 2.5 cm 
area of heterogeneous intermediate-signal intensity lesion disrupting the normal high-signal inten-
sity endometrium and invading less than half of the myometrium (Figure 1). Then, in January 2015, 
she underwent hysterectomy and bilateral oophorectomy. A specimen of the tumor was collected and 
processed for RQ-PCR analysis. The final histopathology reported a 2 cm × 1 cm G2 endometrioid 
FIGURe 2 | Histology of the primary endometrial cancer and the ileum recurrence. (a) Moderately differentiated endometrioid adenocarcinoma (G2). 
Superficial myometrial invasion of the tumor (arrow) (hematoxylin–eosin staining, ×20). (B) Endometrioid adenocarcinoma metastating to the ileum. The tumor 
invades bowel mucosa (arrow) and stroma connective adipose subserous (hematoxylin–eosin staining, ×20).
FIGURe 1 | pelvic magnetic resonance image. Sagittal T2-weighted 
magnetic resonance image showing endometrial cancer as heterogeneous 
intermediate-signal intensity lesion (white asterisk) disrupting the normal 
high-signal intensity endometrium and infiltrating less than half of the ventral 
myometrial thickness (revised FIGO IA Stage).
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EC with a 30% myometrial deep invasion (FIGO Stage 1A) 
(Figure 2A). Concerning the clinicopathological parameters rou-
tinely assessed in EC, lymphovascular space invasion (LVSI) was 
negative, both estrogen receptor (ER) and progesterone receptor 
(PR) were positive, p53 was positive, whereas PTEN was negative. 
The patient was considered as low risk for recurrence; therefore, 
no adjuvant treatment was recommended, and follow-up was 
started.
In July 2015, the patient experienced a dull pelvic pain, starting 
from the right lower quadrant, migrating to the right flank. Physical 
examination revealed tenderness in the right lower quadrant. An 
abdominal ultrasound scan (US) revealed a right-sided grade 2 
hydronephrosis. A total body computer tomography (CT) and 
a pelvic MRI showed two solid lesions: a 5 cm × 3 cm × 3.8 cm 
recurrence at the vaginal vault with infiltration of the left wall 
of the bladder, near the ureterovesical junction, and another 
lesion (16 mm × 8 mm) surrounding the right pelvic ureter that 
caused hydronephrosis. The patient underwent cystoscopy with 
multiple biopsies of the left bladder wall, which were positive for 
recurrence of EC. The patient started six cycles of a three-weekly 
schedule of carboplatin and paclitaxel.
In January 2016, after the first cycle of chemotherapy, the 
patient developed an enterovaginal fistula and subsequently 
an ileal subocclusion. The patient underwent ileal resection, 
omentectomy, as there was macroscopic disease, and fistula 
repair. The final histopathology was positive for EC recurrence 
at ileum, omentum, and vaginal wall (Figure  2B). The patient 
continued chemotherapy. The local Ethical Committee of AOU 
Careggi (Florence, Italy) approved this study. Patient has given 
her written informed consent, in accordance with the Declaration 
of Helsinki.
BaCKGRoUND
Endometrial cancer (EC) is the most common malignancy of the 
female reproductive tract with an increasing incidence (1). In the 
last 10 years, EC has been generally divided into three risk groups: 
high-, intermediate-, and low-risk group (2). Several prognostic 
factors, namely FIGO Stage, depth of myometrial invasion, tumor 
differentiation grade, tumor histotype, and lymphovascular space 
involvement, are currently assessed in EC to classify the patients 
into the three risk groups. Moreover, large clinical trials, such as 
PORTEC-1 and GOG-99, have established other risk factors, i.e., 
older age and tumor size (3, 4). Several molecular markers have 
been reported as predictors of outcome in EC and are likely to 
contribute to future personalized therapy. However, these mol-
ecules are still under investigation and currently not in clinical 
practice (2).
Despite a rather favorable prognosis in low-risk patients, 
4–10% of tumors will recur. The vagina is the most commonly 
affected site by local recurrence (5). Vaginal brachytherapy is a 
recommended adjuvant therapy in only intermediate- and in 
high-risk patient with negative nodes (2). Indeed, prophylactic 
vaginal irradiation in the low-risk group is not recommended, 
FIGURe 3 | Luteinizing hormone receptor (LH/hCG-R) staining in endometrial cancer (eC). (a) Immunohistochemistry (IHC) for LH/hCG-R in the EC 
specimen. Arrow indicates LH/hCG-R staining at the cytoplasmic level. The surrounding endometrial stroma (star) is negative for staining (magnification ×20).  
(B) Immunostaining for LH/hCG-R showing strong positivity also in the ileal metastases. Inset showing a section of corpus luteum used as positive control 
(magnification ×20).
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though still under debate (6, 7). A multicentre randomized 
study, on vaginal brachytherapy in FIGO Stage I low-risk EC, 
reported a lower rate of vaginal recurrence in the treatment 
group compared with the controls, although the difference was 
not statistically significant (7). On the contrary, in ASTEC/EN5 
trial, no benefit of vaginal brachytherapy in low-risk patients was 
found (8). In this group of patients, the average risk of recurrence 
after surgery alone is low and adjuvant retrotranscribed (RT) does 
not increase survival outcomes. Nevertheless, within the low-risk 
patients, there might be subgroups of patients who may benefit 
from vaginal brachytherapy and/or targeted therapies. Therefore, 
additional prognostic tools are needed to improve the definition 
of the risk of recurrence in patients with EC.
DIsCUssIoN
Our patient was 51-year-old women when cancer was diag-
nosed and most of the prognostic factors were known prior to 
surgery by endometrial biopsy and pelvic RMI. Therefore, the 
patient was treated as a low-risk EC with surgery alone and a 
close follow-up. Clinicopathological parameters assessed after 
surgery confirmed the low-risk status of the patient. She had 
a G2 endometrioid EC, FIGO Stage IA, both ER and PR were 
highly expressed, and LVSI was negative. Indeed, in patients 
with EC, higher level of ER and PR predict favorable survival 
(9), and the presence of LVSI is currently considered as an 
independent prognostic factor associated with an increased risk 
of pelvic lymph node metastases and/or relapse of disease (2). 
Finally, even though p53 hotspot mutations are significantly 
more frequently found in serous ECs than in endometrioid EC, 
our patient had p53 positive (10). In some observational studies, 
mutations of p53 have been associated with aggressive forms of 
EC (11, 12), although in the latest guidelines, the presence of 
p53 mutations is not considered in the classification of high-risk 
patients (2).
Six months after surgery, our patient developed an early 
vescico-vaginal recurrence and few months later a subsequent 
involvement of vaginal wall, ileum, and omentum, despite having 
already started chemotherapy.
Various molecular biomarkers have been investigated in 
order to improve the detection of women with increased risk of 
nodal metastases and/or recurrence within each risk group, and 
consequently to tailor surgical staging procedures and adjuvant 
therapies. Identifying the key factors/pathways responsible for 
the aggressiveness of EC is urgently needed in order to address 
the alarming trend of decreasing survival. The Cancer Genome 
Atlas Research Network has recently published an integrated 
genomic, transcriptomic, and proteomic characterization of 373 
endometrial carcinomas (10). The Cancer Genome Atlas data-
base is a large-scale genomic database that primarily envisions 
somatic changes in cancers, including EC. The final goal of the 
study was to tailor patient treatment in a personalized manner 
and drive customization of disease care by implementing tumor 
genetic information. The analysis provided insights into disease 
biology and diagnostic classification of EC into four categories: 
POLE ultramutated, microsatellite instability hypermutated, 
copy-number low, and copy-number high. Nevertheless, these 
molecular factors have not been incorporated into any classifica-
tions for treatment and follow-up of EC since they are still under 
investigation.
Finally, our group contributed to this challenge defining the 
role of LH/hCG-receptor (LH/hCG-R)/luteinizing hormone 
(LH) in EC tumor progression. Our researches have demon-
strated that (i) LH/hCG induces an in vitro invasive phenotype, 
through the activation of LH/hCG-R and hence of protein kinase 
A (PKA) (13); (ii) LH/hCG-R mRNA is expressed in a small cohort 
primary ECs (14); (iii) primary treatment with Gn-RH analogs 
(aimed to decrease the levels of serum LH) for 6 years in a patient 
affected by EC with contraindications to surgery, was associated 
with no evidence of progression of the disease throughout the 
study period (15); (iv) LH/hCG-R in a preclinical mouse model 
of EC behaves as a prometastatic molecular device (16).
In this paper, we describe an LH/hCG-R expression in 
cancer specimens collected at primary diagnosis and at relapse 
and immunohistochemical (IHC) analysis for LH/hCG-R in all 
paraffinated cancer specimens collected at primary diagnosis and 
relapse (Figure 3). The expression turned out to be high in both 
the analyses and in all specimens.
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LH/hCG-R analysis: Methods
(1) RNA isolation, reverse transcription, and RQ-PCR analysis. 
Neoplastic tissues were conserved in RNA-later (Invitrogen) 
and then homogenized in Trizol Reagent (Invitrogen). The 
RNA integrity was assessed with the Agilent 2100 Bioanalyzer. 
One microgram of RNA was RT using random primers and 
reverse transcriptase (SuperScript II Reverse Transcriptase, 
Invitrogen) according to manufacturer’s protocol. cDNA 
was used as template for RQ-PCR analysis with SYBR green 
fluorescent dye (Power SYBR® Green, PCR master mix, and 
Applied Biosystems). The relative expression of genes was 
calculated with the comparative threshold cycle method. The 
GAPDH gene was used as a standard reference, as already 
reported (17). A pool of normal mucosa was used as calibra-
tor for LH/hCG-R expression. Primers used were the fol-
lowing: LH/hCG-R sense TGCCTACCTCCCTGTCAAAG, 
antisense TTGAGGAGGTTGTCAAAGG; a-sma sense 
GACGAAGCACAGAGCAAAAGAG, antisense TGGTGAT 
GATGCCATGTTCTATCG-3′; vimentin sense CCTTGAAC 
GCAAAGTGGAAT; antisense TTTGGACATGCTGTTCC 
TGA (18).
(2) IHC analysis. IHC staining was performed on 3 μm thick 
serial sections cut from formalin-fixed and paraffin-
embedded tissues. As primary antibody we used rabbit poly-
clonal against luteinizing hormone receptor (LHR) (Novus 
Biologicals, Littleton, CO, USA) at dilution 1:50 overnight 
at 4°C. Antigen retrieval is performed in thermostat bath 
(PT Link, Pre-Treatment Module Dako) at 97°C with Citrate 
buffer 10 mM pH 6 for 8 min. For chromogenic detection, 
ultraView Universal RED detection kit (Ventana Medical 
Systems, Tucson, AZ, USA) was used. The sections were 
lightly counterstained with Mayer’s hematoxylin. A nega-
tive control sample was performed by omitting the primary 
antibody. Sections of corpus luteum were used as positive 
control. The control sections were treated in parallel with the 
samples in the same run.
LH/hCG-R analysis: Results
RQ-PCR analysis of EC specimen showed a strong hyper expres-
sion of mRNA for LH/hCG-R, just above 180-fold than normal 
mucosa (mean Ct values are reported in Table 1).
To further characterize the primary tissue sample, we per-
formed a RQ-PCR to determine the expression of fibroblast 
markers (vimentin and α-SMA). The results showed low expres-
sion of vimentin and α-SMA, confirming that the tissue sample 
contain almost exclusively tumor cells (mean Ct values are 
reported in Table 1).
Gene expression levels were evaluated by RQ-PCR using the 
primer pairs reported in materials and methods. Table shows the 
mean ± SD of Ct values of the different transcripts, as well as of 
the housekeeping gene GAPDH.
CoNCLUDING ReMaRKs
Patients with EC are defined as low/intermediate/high risk of 
recurrence based on clinicopathological prognostic factors (2). 
However, such management may lead to undertreatment and, 
among the low-risk group; the most frequent consequence is local 
vaginal relapse (7).
Previous studies by our group in vitro and in preclinical model 
have reported that the over-expression of the LH/hCG-R increases 
the ability of EC cells to undergo local invasion and metastatic 
spread (13, 14, 16). In this paper, we described high levels of 
expression of LH/hCG-R at both mRNA and protein levels in a 
patient with EC who experienced early relapses, even though she 
was defined as low risk according to the current guidelines. For 
this reason, in our opinion, it may be possible to claim that there is 
a relationship between high LH/hCG-R expression and biological 
aggressiveness of EC.
In conclusion, our report suggests that LH/hCG-R expression 
in EC specimens, together with other clinicopathological mark-
ers, should be taken into account in order to assess the risk profile 
in patients with EC. Further clinical trials are warranted in order 
to validate LH/hCG-R as biomarker in low-risk EC.
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taBLe 1 | evaluation by RQ-pCR of the transcript levels of LHR transcript and of fibroblast markers in a primary endometrial cancer specimen.
Ct values GapDH (mean + sD) Ct values LHR (mean + sD) Ct values a-sMa (mean + sD) Ct values vimentin (mean + sD)
Reference 14.770 ± 0.055 36.163 ± 0.723 25.771 ± 0.110 28.083 ± 0.143
Patient 22.126 ± 0.100 36.015 ± 0.625 32.220 ± 0.152 28.083 ± 0.143
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